Diabetes
Refine Search
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Generics
Viatris has disclosed that its oral finished-dose manufacturing facility in Indore, India, is subject to regulatory action from the US regulator, after an inspection earlier this year. 24 December 2024
Generics
The US Food and Drug Administration (FDA) revealed on Monday that it has approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter. 24 December 2024
Pharmaceutical
US pharma major Eli Lilly has recently announced a £279 million ($365.5 million) investment in the UK at the International Investment Summit in London. 19 December 2024
Pharmaceutical
The Egyptian Drug Authority has approved EVA Pharma's insulin glargine injection, marking a significant milestone in its collaboration with US pharma major Eli Lilly. 18 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Biotechnology
Novavax has agreed to sell its manufacturing plant in the Czech Republic to Novo Nordisk for $200 million. 6 December 2024
Pharmaceutical
Novo Nordisk will reduce the US list prices of two insulin products, Tresiba (insulin degludec) and Fiasp (insulin aspart), by over 70% from 2026. 6 December 2024
Pharmaceutical
Eli Lilly has announced a $3 billion investment to expand its recently acquired manufacturing facility in Wisconsin, USA. 6 December 2024
Pharmaceutical
Danish diabetes and obesity giant Novo Nordisk has announced plans to invest 2.9 billion Danish kroner ($410 million) to establish a cutting-edge quality control laboratory in Hillerød, Denmark. 6 December 2024
Biotechnology
Dutch privately held Amarna Therapeutics, which specializes in transformative gene therapies, has entered into a strategic collaboration with Sweden-based NorthX Biologics, a leading biologics manufacturing partner. 4 December 2024
Pharmaceutical
The China-based subsidiary of French pharma major Sanofi revealed it has signed a memorandum of cooperation with Beijing Municipal Bureau of Economy and Information Technology and Beijing Economic and Technological Development Zone today to invest approximately 1 billion euros ($1.05 billion) to establish a new manufacturing base. 3 December 2024
Pharmaceutical
Hua Medicine has announced promising new clinical findings for its glucokinase activator dorzagliatin, presented at the China BioMed Innovation and Investment Conference. 2 December 2024
Pharmaceutical
Australia’s Department of Health and Aged Care has developed a new API (application programming interface) for the efficient distribution of the monthly Pharmaceutical Benefits Scheme (PBS) schedule data. 2 December 2024
Biotechnology
Privately-held UK firm Quell Therapeutics, which positions itself as a pioneer in developing engineered T-regulatory (Treg) cell therapies for serious medical conditions driven by the immune system, has announced that AstraZeneca has selected a candidate to progress in the type 1 diabetes (T1D) Treg cell therapy program. 18 November 2024
Pharmaceutical
French pharma major Sanofi today announced an investment of 40 million euros ($42.4 million) in its Lyon Gerland bioproduction site, consolidating its role as a strategic platform dedicated to immunology. 15 November 2024
Pharmaceutical
Privately-held Montanan firm Microbion has announced promising findings from its Phase II study of pravibismane, a topical treatment aimed at addressing diabetic foot ulcer infections (DFI). 14 November 2024
Pharmaceutical
While sky high expectations for Eli Lilly’s tirzepatide have not yet been realized, more positive data add to a growing sense that the future could be as bright as imagined. 14 November 2024
Pharmaceutical
Germany’s Merck KGaA was trading 5% lower as Thursday’s trading day neared its end, after the company announced its third-quarter financial results and outlook for the rest of the year. 14 November 2024
Pharmaceutical
Anglo-Swedish drugmaker AstraZeneca beat analyst expectations with its third-quarter 2024 revenue and earnings figures. 12 November 2024
Pharmaceutical
The American Diabetes Association (ADA) 75th annual meeting kicked off over the weekend in Boston with a plethora of news on investigational and already marketed diabetes treatments, among which were the following: 7 June 2015
Pharmaceutical
French pharma major Sanofi’s subsidiary Genzyme has been granted Breakthrough Therapy designation for its investigational drug olipudase alfa by the US Food and Drug Administration. 4 June 2015
Biotechnology
Japanese drug major Astellas Pharma has entered into an agreement with privately-held Swiss biotech firm Anokion to collaborate in the fields of type 1 diabetes and celiac disease. 3 June 2015
Pharmaceutical
In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether Danish diabetes care giant Novo Nordisk’s Tresiba (insulin degludec), alone or in combination with other blood-glucose lowering drugs, offers an added benefit over the appropriate comparator therapy. 2 June 2015
Pharmaceutical
Boehringer Ingelheim and partner US peer Eli Lilly’s Synjardy (empagliflozin/metformin) has been granted marketing authorization by the European Commission for the treatment of adults with type 2 diabetes (T2D) in the European Union. 28 May 2015
Pharmaceutical
High blood-glucose levels could be linked to the risk of Alzheimer’s disease and other forms of dementia, according to two recently-published studies. 26 May 2015
Pharmaceutical
The US Food and Drug Administration is warning that several type 2 diabetes drugs, called sodium-glucose cotransporter-2 (SGLT2) inhibitors, may lead to ketoacidosis, a serious condition where the body produces high levels of blood acids called ketones that may require hospitalization. 16 May 2015
Pharmaceutical
AstraZeneca has entered an agreement with US health care firm Abbott to develop companion diagnostic tests to identify patients with severe asthma who are most likely to benefit from the investigational biological therapy tralokinumab. 13 May 2015
Biosimilars
India’s Biocon, Asia’s premier biotechnology company, says that it has made clinical progress in its partnered programs with US generics major Mylan. 11 May 2015
Pharmaceutical
New data from a post-hoc analysis of the Phase IIIa SCALE clinical trial program were presented at the European Congress on Obesity (ECO), demonstrating the weight-loss-dependent and independent effects of Danish diabetes care giant Novo Nordisk’s Saxenda (liraglutide 3mg). 8 May 2015
Biosimilars
The Australian Generic Medicines Industry Association (GMiA) says it welcomes the decision of the Pharmaceutical Benefits Advisory Committee (PBAC) to consider “a” flagging of biosimilars, and to list biosimilar insulin (Basaglar) on the Pharmaceutical Benefits Scheme (PBS). 1 May 2015
Pharmaceutical
Danish diabetes care giant Novo Nordisk posted first quarter 2015 financials this morning, showing that net sales increased 24% (+9% in local currencies) to 25.20 billion Danish kroner ($3.67 billion). 30 April 2015
Pharmaceutical
French drug major Sanofi has been granted marketing authorization in Europe for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL) by the European Commission. 29 April 2015
Pharmaceutical
French pharma major Sanofi plans to start exports of insulin from its existing Russian plant to the European Union countries and the Middle East region, according to the company. 29 April 2015
Pharmaceutical
Japan’s largest drugmaker Takeda Pharmaceutical and its US subsidiary, have reached an agreement expected to resolve the vast majority of Actos (pioglitazone) product liability law suits pending against Takeda in the USA. 29 April 2015
Pharmaceutical
Novo Nordisk says that Saxenda (liraglutide [rDNA origin] injection) is now available in the USA, the first market to get the product. 22 April 2015
Biotechnology
Japan’s Center for iPS Cell Research Application (CiRA) of Kyoto University looks set to earn as much as 20 billion yen (around $168 million) from the country’s largest drugmaker, Takeda Pharmaceutical. 19 April 2015
Pharmaceutical
US pharma giant Merck & Co and Japan’s Astellas Pharma last week signed a memorandum of understanding regarding co-development and co-commercialization of a combination product of Januvia (sitagliptin) and Suglat (ipragliflozin L-proline), in Japan. 19 April 2015
Pharmaceutical
USA-based Targacept has announced top-line results from a Phase I/II exploratory study of TC-6499 as a treatment for diabetic gastroparesis, a chronic disorder that slows or stops the passage of food from the stomach to the small intestine. 17 April 2015
Pharmaceutical
A US Food and Drug Administrationadvisory panel has voted to recommend that labels for UK pharma major AstraZeneca’sdiabetes drug Onglyza (saxagliptin) and Kombiglyze (saxagliptin/metformin) include a warning regarding a potential risk of heart failure and death. 15 April 2015
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze